Document text
Principal Investigator: David J Erle
Organization: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Fiscal Year: 2020
Award: $99,855
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that
has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors.
Indeed, disease severity varies markedly based on recognized clinical risk factors (age and co-morbidities).
The biological underpinnings of this clinical variability are unknown but likely relate to variation in both the virus
and the host response. A detailed understanding of the risk factors for severe disease, including genetic and
environmental factors and the nature of the host immunological response, is essential for the development of
prognostic biomarkers and effective therapies. To meet this urgent need we propose to help develop and to
participate in the IMPACC multi-center longitudinal clinical study of hospitalized patients with COVID-19 and to
immunophenotype participants using shared immunological methods that will be designed an carried out by
core laboratories at UCSF and at other participating institutions. Our specific aims are 1) to develop a
prospective observational convenience cohort of adult subjects hospitalized with known or presumptive
COVID-19, 2) to use this cohort to describe the relationship between specific immunologic assessments and
clinical course of COVID-19 in hospitalized patients, and 3) to implement three core laboratories at UCSF to
support immunophenotyping in this multicenter cohort. These core laboratories will perform bulk RNA
sequencing of blood peripheral blood mononuclear cells (PBMC), bulk metagenomic next-generation
sequencing (mNGS) on endotracheal aspirate samples, and serologic phage display assays (PhIP-Seq).
Successful completion of these aims will yield critical information regarding the relationship between viral load,
host immunological responses, and poor clinical outcomes that are urgently needed for biomarker
development and rational therapeutic targeting. In addition, the cellular samples banked in this study may
directly contribute to the development of neutralizing antibodies and vaccine strategies that will be our ultimate
defense against recurrence of this extraordinary pandemic. A rapid and robust scientific and medical response
of the type proposed by the NIAID and the academic community in this consortium is an essential element of a
broad response required to protect the health and well-being of all individuals, our health care system, and the
broader social structures that maintain global health and welfare.
Terms: <2019 novel coronavirus><2019-nCoV><21+ years old><Adult><Adult Human><Affect><Age><Aspirate><Aspirate substance><Assay><Bioassay><Biologic Assays><Biological><Biological Assay><Blood Serum><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Case Fatality Rates><China><Chronic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Communities><Coronaviridae><Coronavirus><DNA Sequencing Facility><Development><Diabetes Mellitus><Disease><Disease Outcome><Disorder><Drugs><Elements><Enrollment><Environmental Factor><Environmental Risk Factor><Family><Functional Metagenomics><General Hospitals><Genetic><Genetic Risk><Health><Health Care Systems><Healthcare Systems><Hypertension><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune response><Immunochemical Immunologic><Immunodeficiency and Immunosuppression Disorders><Immunologic><Immunologic Diseases><Immunologic Subtyping><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunological response><Immunologically><Immunologics><Immunophenotyping><Individual><Infection><Institution><Intervention><Intervention Strategies><Investigation><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Laboratories><Lung diseases><Mainland China><Medical><Medical center><Medication><Metagenomics><Methods><Molecular Marker of Prognosis><Myocardial Ischemia><NGS Method><NGS system><NIAID><National Institute of Allergy and Infectious Disease><Nature><Onset of illness><Outcome><PBMC><Participant><Pathogenicity><Patients><Peripheral Blood Mononuclear Cell><Personal Satisfaction><PhIP-seq><Phage Display><Phage ImmunoPrecipitation Sequencing><Pharmaceutic Preparations><Pharmaceutical Preparations><Pneumonia><Prognosis Marker><Prognostic Marker><Pulmonary Diseases><Pulmonary Disorder><RNA Seq><RNA sequencing><RNAseq><Recurrence><Recurrent><Research Resources><Resources><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Risk Factors><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sample Size><Sampling><San Francisco><Sequencing Core><Serologic><Serological><Serum><Severe acute respiratory syndrome coronavirus 2><Severity of illness><Site><Therapeutic Agents><Variant><Variation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Viral Burden><Viral Load><Viral Load result><Virus><Wuhan coronavirus><access to health care><access to healthcare><accessibility of health care><accessibility to health care><accessibility to healthcare><adulthood><ages><base><biomarker development><cardiac ischemia><clinical center><clinical risk><co-morbid><co-morbidity><cohort><comorbidity><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronary ischemia><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><design><designing><developmental><diabetes><disease of the lung><disease onset><disease severity><disorder of the lung><disorder onset><drug/agent><effective therapy><effective treatment><endotracheal><enroll><environmental risk><global health><health care access><health care availability><health care service access><health care service availability><healthcare access><healthcare accessibility><healthcare availability><healthcare service access><healthcare service availability><heart ischemia><high blood pressure><host response><hyperpiesia><hyperpiesis><hypertensive disease><immunophenotype><immunoresponse><improved><inclusion criteria><interventional strategy><lung disorder><member><mortality><myocardial ischemia/hypoxia><myocardium ischemia><neutralizing antibody><neutralizing vaccine><new drug treatments><new drugs><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><novel virus><pandemic><pandemic disease><pathogen><peripheral blood><prognostic biomarker><prognostic indicator><prospective><respiratory><response><social structural><social structure><socio-structural><sociostructural><therapeutic target><transcriptome sequencing><trauma centers><welfare><well-being><wellbeing>